PUBLISHER: Grand View Research | PRODUCT CODE: 1553421
PUBLISHER: Grand View Research | PRODUCT CODE: 1553421
The global process analytical technology market size is expected to reach USD 10.91 billion by 2030, registering a CAGR of 5.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising R&D spending by pharmaceutical companies, government investment in emerging markets, growing adherence to reliability by design (QbD) principles, increasing emphasis on improving quality and manufacturing process efficiency, and technological developments in the analytical technology industry are the main drivers in the market.
Process analytical technology is crucial to the manufacturing of pharmaceuticals as it provides data that aids in decision-making, quality assurance, product development, and factory implementation. Such technology also aids in spotting possible issues, such as contamination or foreign materials, in drug production procedures. Process analytical technology can detect contamination at levels as low as 0.1 parts per million, according to a report on the global process analytical technology. This could result in considerable time and financial savings and further boost the adoption of analytical technology in bioprocessing.
The COVID-19 pandemic has been a significant growth driver for several process analytical technology offerings. The search for efficient preventive and curative medications is intensifying in response to rising infection and mortality rates. Due to the fact that process analytical technology is largely used to monitor and assess the drug development process, demand for it significantly increased in 2020. For instance, in August 2022, as per the article published on InsideTele, modernizing synthesis workstations, offering precise reactor control, enabling the capture and digitalization of response process information, and securing the reproducibility as well as the link among users, experiments, and sites are all possible with the use of process analytical technology in drug formulation.
Due to the numerous benefits the technology provides, including lower production costs, lower capital expenditures, the desired quality, time savings, and the flexibility to allow pharmaceutical companies to direct their resources to other areas, such as marketing, the trend of outsourcing the production of pharma products to pure CMOs has risen significantly in recent years. For instance, in July 2021, Arvinas Inc. and Pfizer Inc. established a worldwide partnership to manufacture and market ARV-471, an experimental oral PROTAC (proteolysis-targeting-chimera) estrogen receptor protein degrader. This is, in turn, driving the market for process analytical technology.
It is anticipated that the adoption of new and better process analytical technology by key industry players will accelerate the expansion of the global market. For instance, in November 2021, Thermo Fisher Scientific launched MS & chromatography equipment during the Human Proteome Organization (HUPO) Reconnect event. For proteomics investigations, the high-resolution Thermo Scientific Orbitrap MS equipment is complemented by the Thermo Scientific Vanquish Neo UHPLC system, which reduces the loss of sample and produces data of the best possible quality. It is intended for high-sensitive LC-MS applications and has strong analytical efficiency at a rate of flow that ranges from 1 nL/min to 100 L/min up to 1,500 bar.